China National Accord Medicines Corporation (200028)
- 12.00
- -0.01-0.08%
China National Accord Medicines Corporation (200028) News
Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight
The non-metastatic prostate cancer market is expected to witness significant growth, driven by increasing disease awareness, improved screening practices, and advances in early-stage diagnosis.
Sinopharm United: First Quarter Report for 2026
Sinopharm United: Preliminary First-Quarter 2026 Results
China National Accord Medicines' Q1 Profit Slips 12%
China National Accord Medicines' (SHE:000028, SHE:200028) attributable profit fell 12% in the three months ended March 31 to 287.5 million yuan from 328 million yuan a year prior, according to a
Sinopharm United: 2025 Annual Report
Sinopharm United: Summary of the 2025 Annual Report